Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PTI’s Remoxy: Negative FDA Panel Review May Be The End Of Abuse-Deterrent Opioid's Road

Executive Summary

Concerns that the extended-release oxycodone product poses the same potential for intravenous abuse as Endo’s withdrawn Opana ER drive FDA advisory committee recommendation against approval, laying the groundwork for a fourth complete response letter; FDA’s comparison of Remoxy to Opana during the meeting ‘borders on slanderous,’ PTI CEO Barbier tells Scrip, predicting sponsors will be dissuaded by the shifting regulatory goalposts for abuse-deterrent formulations.


Advertisement

Related Content

Pain Therapeutics Appeals Remoxy CRL In Likely Last Ditch Effort To Save Abuse-Deterrent Opioid
Keeping Track: Poteligeo, Onpattro, Galafold And Annovera Approved; Selinexor Submitted
Not Another Opana: US FDA Panel Rejects PTI’s Remoxy On Intravenous Abuse Concerns
Abuse-Deterrent Opioids: Where Are They Now?
Opana ER Withdrawal Adds Weight To Endo's Ongoing Revenue Decline
FDA Requests Withdrawal Of Endo's Opana ER
FDA Moves On Endo’s Opana ER Unlikely To Sweep Up Other Opioids
Pfizer's surprise Remoxy withdrawal slashes Pain, Durect prices by half

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123333

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel